Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Vektor Medical Appoints Kelly Perez as CFO and SVP of Operations
Vektor Medical, a medical technology company transforming cardiac arrhythmia care, announced the appointment of Kelly Perez as Chief Financial Officer (CFO) and Senior Vice President of Operations, strengthening its leadership team as adoption of vMap accelerates.
SimBioSys and Ricoh 3D Expand Access to TumorSight For Breast Cancer Surgery
SimBioSys, a clinical AI company that uses spatial biophysics to help make breast cancer treatments more precise, has signed a strategic, non-exclusive agreement with Ricoh 3D for Healthcare, LLC. Ricoh 3D for Healthcare is part of Ricoh USA, Inc. and makes FDA-approved, patient-specific medical devices both in central facilities and at the point of care. This partnership is meant to make TumorSight Viz, SimBioSys’s FDA-approved 3D surgical visualization tool for breast cancer surgery, more widely available.
Bioretec Appoints Sarah van Hellenberg Hubar-Fisher as CEO
Bioretec Ltd., a top company in absorbable orthopedic implants, has officially named Sarah van Hellenberg Hubar-Fisher as its new Chief Executive Officer, effective immediately. She has been acting as CEO since May 2025 and has been part of the company’s Board of Directors since 2021. With a strong background in medtech leadership, van Hellenberg Hubar-Fisher is taking on this role with a focus on growing Bioretec’s business after key regulatory successes.
MedaSync Secures Strategic Investment from Omega Healthcare Investors
MedaSync, a top company that offers AI-powered software to help skilled nursing facilities with reimbursement processes, has received a strategic investment from Omega Healthcare Investors, Inc., a leading real estate investment trust focused on skilled nursing and assisted living facilities. This partnership will help MedaSync speed up the release of smart tools aimed at making administrative tasks easier across the skilled nursing industry. MedaSync is already gaining a lot of traction, with customer growth more than doubling compared to the previous year.
Replicate, Novo Nordisk Partner on RNA Therapies for Diabetes
Replicate Bioscience, a clinical-stage biotech company leading the development of next-generation self-replicating RNA (srRNA) technology, has entered into a major multi-year partnership with Novo Nordisk, a global leader in healthcare. The collaboration aims to develop new srRNA-based therapies targeting obesity, type 2 diabetes, and other cardiometabolic conditions. By combining Novo Nordisk’s deep clinical and therapeutic expertise with Replicate’s cutting-edge srRNA platform—which enables the body’s own cells to produce therapeutic proteins—the partnership is set to advance innovative treatments for some of the world’s most prevalent chronic diseases. Under the terms, Novo Nordisk will receive an exclusive global license to use Replicate’s srRNA platform for specific targets, while Replicate will benefit from research funding, an upfront payment, and potential milestone-based payments of up to $550 million, along with royalties from future product sales.
To share your insights, please write to us at sudipto@intentamplify.com
